Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs ... 36 days in a phase 1 readout in September. Metsera has ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

She’s maintaining her weight loss on a less-frequent dose of the GLP-1 and is expecting to complete her second marathon at an ...

Supplements promising similar results to Ozempic have taken over social media, but the TGA and health experts have concerns.

potential once-monthly injectable GLP-1 RA engineered with Metsera’s HALO™ lipidation platform. MET-097i showed a 7.5% reduction in body weight from baseline at day 36 and a 380-hour half-life.

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...